webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

SPDP

  CAS No.: 68181-17-9   Cat No.: BADC-00372   Purity: ≥ 97% (HPLC) HPLC MS HNMR 4.5  

SPDP is a heterobifunctional ADC crosslinker featuring NHS ester and cleavable disulfide bonds. Used in antibody-drug conjugates for thiol-reactive bioconjugation, it supports controlled drug release under reductive conditions. Ideal for constructing cleavable linkers in targeted delivery systems.

SPDP

Structure of 68181-17-9

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C12H12N2O4S2
Molecular Weight
312.37
Shipping
Room temperature
Shipping
Store at -20 °C

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
1 g $299 In stock
5 g $419 In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
N-Succinimidyl 3-(2-Pyridyldithio)Propionate; UNII-2OHG8V08NL; SPDP NHS Ester; 3-(2-Pyridyldithio)Propionic Acid N-Hydroxysuccinimide Ester
IUPAC Name
Canonical SMILES
c1ccnc(c1)SSCCC(=O)ON2C(=O)CCC2=O
InChI
InChI=1S/C12H12N2O4S2/c15-10-4-5-11(16)14(10)18-12(17)6-8-19-20-9-3-1-2-7-13-9/h1-3,7H,4-6,8H2
InChIKey
JWDFQMWEFLOOED-UHFFFAOYSA-N
Density
1.48 g/cm3
Solubility
Soluble in DMSO
Melting Point
84-86°C(lit.)
Appearance
White powder
Quantity
Grams-Kilos
Quality Standard
Enterprise Standard
Shelf Life
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Shipping
Room temperature
Storage
Store at -20 °C
Pictograms
Irritant
Signal Word
Warning
Boiling Point
465.9°C at 760 mmHg
NCT NumberCondition Or DiseasePhaseStart DateSponsorStatus
NCT02968433Parkinson Disease(PD)Phase 12020-12-30Stanford UniversityCompleted
1.Molecular understanding of sterically controlled compound release through an engineered channel protein (FhuA).
Güven A1, Fioroni M, Hauer B, Schwaneberg U. J Nanobiotechnology. 2010 Jun 25;8:14. doi: 10.1186/1477-3155-8-14.
BACKGROUND: Recently we reported a nanocontainer based reduction triggered release system through an engineered transmembrane channel (FhuA Delta1-160; Onaca et al., 2008). Compound fluxes within the FhuA Delta1-160 channel protein are controlled sterically through labeled lysine residues (label: 3-(2-pyridyldithio)propionic-acid-N-hydroxysuccinimide-ester). Quantifying the sterical contribution of each labeled lysine would open up an opportunity for designing compound specific drug release systems.
2.3-(2-pyridyldithio)propionic acid hydrazide as a cross-linker in the formation of liposome-antibody conjugates.
Ansell SM1, Tardi PG, Buchkowsky SS. Bioconjug Chem. 1996 Jul-Aug;7(4):490-6.
Liposome antibody conjugates are potentially useful as a means of targeting drugs to specific tissues. A new protocol for the conjugation of IgG to maleimide-containing liposomes was developed using 3-(2-pyridyldithio)propionic acid hydrazide (PDPH) as a cross-linker. Periodate-oxidized antibody was treated with PDPH to yield a hydrazone derivative. Deprotection with DTT produced a thiolated antibody which was then conjugated to liposomes containing N-[4-(p-maleidophenyl)butyryl]-1,2-sn-distearoylphosphatidyleth anolamine. The liposome-antibody conjugates were found to have in vitro properties similar to those of conjugates formed by the traditional 3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide ester (SPDP) protocol but were cleared less rapidly in circulation. The PDPH protocol presents a viable alternative to SPDP, particularly for antibodies sensitive to amine modification.
3.Synthesis and in vitro T-cell immunogenicity of conjugates with dual specificity: attachment of epitope peptides of 16 and 38 kDa proteins from Mycobacterium tuberculosis to branched polypeptide.
Wilkinson KA1, Vordermeier H, Wilkinson RJ, Ivanyi J, Hudecz F. Bioconjug Chem. 1998 Sep-Oct;9(5):539-47.
T-cell epitope containing peptides covalently attached to macromolecular carriers can be considered as synthetic immunogens for the development of skin-test diagnostics and of vaccines. As a carrier, an amphoteric branched chain polypeptide, poly[Lys-(Glui-DL-Alam)] (EAK) with poly(L-lysine) backbone has been used. This polypeptide with free alpha-amino and gamma-carboxyl groups at the end of the side chains was conjugated with peptides representing two immunodominant regions of the 16 and 38 kDa proteins of Mycobacterium tuberculosis, respectively. Peptide C91SEFAYGSFVRTVSLPVGADE110 was elongated by Cys at the N-terminal and attached to the carrier containing protected SH groups to form disulfide bridges. Peptide 65FNLWGPAFHERYPNVTITA83 was conjugated to the 3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide ester (SPDP) modified and acetylated EAK by introducing amide bond between the free alpha-amino group of peptide and the free gamma-COOH group of Glu at the terminal position of the branches.
4.Homogeneous liposome immunoassay for insulin using phospholipase C from Clostridium perfringens.
Lim SJ1, Kim CK. Anal Biochem. 1997 Apr 5;247(1):89-95.
A new homogeneous liposome immunoassay system was developed in which analyte-phospholipase C conjugates are used instead of complement or melittin. This system was applied for the determination of insulin. Liposomes incorporated with calcein as a marker were prepared by the reverse-phase evaporation method. The lysis of liposomes was determined by measuring the fluorescence intensity of calcein released from liposomes and it was increased with increasing concentration of phospholipase C. Insulin was conjugated to phospholipase C by a three-step procedure with hetero-bifunctional crosslinking reagents, succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate and 3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide ester. The lytic activity of phospholipase C was not affected by the reaction for conjugation. Both p-nitrophenylphosphatidylcholine hydrolytic activity and liposome lytic activity of insulin-phospholipase C conjugate were inhibited in the presence of insulin antiserum.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: MC-VC-PAB-DMEA-PNU159682 | Mc-Val-Cit-PABC-PNP | MC-Val-Cit-PAB-NH-C2-NH-Boc | Mc-Val-Cit-PAB-Cl | MC-Val-Cit-PAB-tubulysin5a | MC-Val-Cit-PAB-vinblastine | MC-Val-Cit-PAB-carfilzomib | N-Succinimidyl 4-(N-maleimidomethyl) trans-cyclohexane 1-carboxylate | Tubulysin IM-1 | Tubulysin IM-2 | SPDP
Send Inquiry
Verification code
Inquiry Basket